Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

LAWSUIT INVESTOR NOTICE: Investors who lost money with Capricor Therapeutics, Inc. (NASDAQ: CAPR) shares should contact the Shareholders Foundation

businesswire.com
CAPR The article is a lawsuit investor notice, indicating potential negative developments or allegations against Capricor Therapeutics, Inc. that have caused investors to lose money.

LAWSUIT INVESTOR NOTICE: Investors who lost money with Capricor Therapeutics, Inc. (NASDAQ: CAPR) shares should contact the Shareholders Foundation SAN DIEGO--( BUSINESS WIRE)--The Shareholders Foundation, Inc. announced that a lawsuit was filed for certain investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) shares in the U.S. District Court for Southern District of California (No: 3:26-cv-04385).

Investors, who purchased a significant amount of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025 and July 26, 2026, in excess of $100,000 have certain options and there are short and strict deadlines running. Deadline: September 28, 2026. NASDAQ: CAPR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

On July 30, 2026, an investor in NASDAQ: CAPR shares filed lawsuit over alleged securities laws violations by Capricor Therapeutics, Inc. The plaintiff alleges that the defendants made false and/or misleading statements and/or failed to disclose that Capricor Therapeutics, Inc. adopted changes to the pre-specified statistical analysis plan used to analyze clinical data for Deramiocel, that the FDA had not agreed to those changes before Capricor Therapeutics, Inc. resubmitted the Deramiocel Biologics License Application (“BLA”), that as a result, there was a significant risk that the FDA could conclude the clinical results did not provide substantial evidence of effectiveness of Deramiocel, and that as a result of the foregoing, there was a substantial risk to regulatory approval of Deramiocel for the treatment of Duchenne muscular dystrophy.

Those who purchased Capricor Therapeutics, Inc. (NASDAQ: CAPR) shares should contact the Shareholders Foundation, Inc.

The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.